While Sarclisa (isatuximab) is a prominent CD38 antibody used in the treatment of multiple myeloma, there are other CD38 antibodies available. One such antibody is Darzalex (daratumumab), which has been approved for use in multiple myeloma and certain types of lymphoma. Darzalex works by targeting CD38, a protein found on the surface of myeloma cells. Additionally, another CD38 antibody called Mor202 is currently being investigated in clinical trials for its potential in treating multiple myeloma and other CD38-expressing malignancies. These antibodies, like Sarclisa, aim to harness the immune system to target and destroy cancer cells expressing CD38.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/SARCLISA
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463192/
[3] https://www.ema.europa.eu/en/documents/assessment-report/sarclisa-epar-public-assessment-report_en.pdf